We scan new podcasts and send you the top 5 insights daily.
Neil Warma says ProMIS designed PMN310 to bind only toxic oligomer species of amyloid beta, avoiding plaque. He notes plaque-clearing drugs can cause ARIA swelling/bleeding, and plaque removal alone doesn't stop cognitive decline. He says the antibody must avoid plaque while hitting upstream oligomers. This selectivity is the core best-in-class bet.
The company focuses on disease-specific 3D protein conformations, which exposes new binding sites (epitopes) not present on the same protein in healthy cells. This allows for highly selective drugs that avoid the toxicity common with targets defined by genetic sequence alone.
Bio Arctic is applying its successful Alzheimer's playbook to Parkinson's disease. This involves a highly selective compound that targets only the toxic protein aggregates (alpha-synuclein) while sparing healthy forms, combined with ensuring patients with the correct pathology are selected for trials.
The focus in Alzheimer's treatment is moving from merely slowing decline in late-stage patients to early prevention. By using anti-amyloid drugs to clear plaques before significant brain damage occurs, it may be possible to prevent the disease's onset entirely.
Voyager CEO Al Sandrock suggests the 30% average efficacy of new Alzheimer's drugs isn't uniform. Instead, some patients may see a complete halt in progression while others see no benefit. He argues the next critical step is predicting these responders, which will determine whether future therapies like anti-tau agents should be added on or used as a replacement.
The next era of CNS drug development will shift from single-target therapies for late-stage disease to early intervention. This involves using biomarkers to detect disease before symptoms appear and intervening with multimodal approaches that address multiple biological pathways simultaneously, such as amyloid, tau, and metabolic deficits in Alzheimer's.
Traditional Alzheimer's drug development has heavily targeted extracellular amyloid-beta plaques with limited success. Retro Biosciences focuses upstream on cellular autophagy failure—the breakdown of the cell's natural system for recycling broken, misfolded proteins. Enhancing intracellular autophagy clears internal protein gunk before it becomes extracellular pathology, offering a biologically grounded, disease-modifying approach rather than treating visible end-stage debris.
Current amyloid treatments like Kisunla face biological limits in early symptomatic Alzheimer's because tau pathology takes over later in disease progression. Eli Lilly's Trailblazer 3 trial investigates treating patients with amyloid biological hallmarks before symptoms appear. Ricks argues that amyloid intervention matters most upstream, which could redefine clinical efficacy and testing paradigms across neurology.
Antibodies bind to specific amino acid sequences, making them unable to distinguish between a protein's healthy and toxic structural forms. Alt-Pep's synthetic peptides use a complementary structure (alpha-sheet) to selectively bind only the toxic oligomers, enabling both targeted therapy and highly specific diagnostics.
The speaker positions NKEVs not as a monotherapy but as a foundational treatment. A key hypothesis is that by clearing amyloid from the brain's vasculature, NKEVs could mitigate the brain bleeding (ARIA) side effects that have plagued anti-amyloid antibody therapies. This would make combination treatments both safer and more effective.
Warma says drugs can completely eliminate plaque while patients continue to decline, and plaque-binding drugs carry ARIA risk. He argues the industry now sees toxic oligomers as the subspecies driving cognitive decline, making plaque a less relevant or insufficient target. That shift explains why ProMIS is not chasing plaque clearance as its main endpoint.